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Abstract 
Objectives  
PD-L1 expression on tumour cells can guide the use of anti-PD-1/PD-L1 
immune modulators to treat patients with non-small cell lung cancer (NSCLC). 
Heterogeneity of PD-L1 expression both within and between tumour sites is a 
well-documented phenomenon that compromises its predictive power. Our 
aim was to better characterise the pattern and extent of PD-L1 heterogeneity 
with a view to optimising tumour sampling and improve its accuracy as a 
biomarker.  
Materials and Methods 
Expression of PD-L1 was assessed by immunochemistry using the SP263 clone 
in 107 resected primary NSCLCs and their nodal metastases.  Intra-tumoural 
heterogeneity, defined as ‘small-scale’ (mm²), ‘medium-scale’ (cm²) and ‘large-
scale’ (between tumour blocks), was assessed by digital imaging using a novel 
‘squares method’.  Inter-tumoural heterogeneity between the primary 
tumours and their nodal metastases and between N1 and N2 nodal stages was 
also assessed.  
Results 
The majority of tumours demonstrated intra-tumoural heterogeneity (small-
scale 78%, medium-scale 50%, large-scale 46%). Inter-tumoural heterogeneity 
between the primary and nodal metastases was present in 53% of cases and, in 
17%, between N1 and N2 disease. These differences were occasionally 
sufficient to lead to discrepancy across the ≥1%, ≥25% and ≥50% cut-offs used 
to guide therapy. 
Conclusion 
Heterogeneity of PD-L1 expression is common, variable in scale and extent, 
and carries significant implications for its accuracy as a predictive biomarker.  
Extensive sampling reduces, but cannot eliminate, this inaccuracy.    
Keywords: PD-L1, programmed-death ligand-1, NSCLC, heterogeneity, nodal 
metastases 
 
 
 
 
 
 
1 Introduction 
The treatment of patients with non-small cell lung cancer (NSCLC)1 has been 
revolutionised by the emergence of immune-checkpoint inhibitors or ‘immune 
modulators’ (IMs), particularly those targeted against tumours exploiting the 
PD-1/PD-L1 (programmed death-1; programme death ligand-1) checkpoint as a 
mechanism of immune escape. 1-4  Currently, the level of expression of PD-L1 
as detected by immunohistochemistry (IHC) is the only accepted biomarker for 
guiding the use of IMs to treat NSCLC, numerous clinical trials having shown 
that expression of PD-L1 by the tumour or tumour-associated immune cells is 
related to response to the drug.1-6  Despite its rapid implementation in the 
routine profiling of NSCLC, PD-L1 expression as a predictor of response has 
several weaknesses compromising its predictive power.  Amongst these are the 
multiplicity of assays, differing expression level percentage cut-offs for 
assigning ‘positive’ status and guiding therapy, and the biological fact that PD-
L1 expression is heterogeneous.7,8  These drawbacks have resulted in a 
confusing, mixed status of PD-L1 IHC as both a companion and complementary 
diagnostic and have raised justifiable doubts about its efficacy.7-13   Despite 
these doubts, reliance on PD-L1 IHC for predicting response of NSCLC to IMs 
 
1 Abbreviations: PD-L1, programmed-death-ligand-1; IHC, immunohistochemistry; IM, immuno-modulators; TPS, tumour proportion score; 
COV, co-efficient of variation; IOD, index of dispersion 
means it is imperative that, in the absence of alternative proven biomarkers, 
every effort should be made to maximise its utility in guiding clinical decision-
making. 
Crucial to addressing the problem of heterogeneity in the context of assessing 
PD-L1 expression is knowing how best to sample the tumour.  Many clinical 
specimens used for the diagnosis, classification and profiling of NSCLC, 
including endoscopic bronchial ultrasound (EBUS)-guided aspirates, 
endobronchial and transthoracic needle biopsies, are very small, and sampling 
error is problematic in obtaining maximum accuracy. 8,14-16 Understanding the 
pattern and extent of heterogeneity of PD-L1 expression is a prerequisite for 
developing and adapting approaches to tumour sampling and ultimately 
increasing the predictive power of the test.  In order to help address this 
challenge, we thought it would be of value to try and assess the pattern and 
extent of intra-tumoural and inter-tumoural heterogeneity of PD-L1 expression 
and thereby develop some practical guidance for those obtaining these crucial 
specimens.  
 
 
 
2 Materials and Methods 
2.1 Specimens studied 
We studied 107 resected NSCLCs consecutively collected and archived by the 
Liverpool Lung Project (LLP) between 2009 and 2014.  Tumours were classified 
according to the then current World Health Organisation 2015 criteria17 and 
staged according to the then current seventh edition of the Union for 
International Cancer Control (UICC) TNM staging system.18 Every primary 
pulmonary tumour was accompanied by metastases in lymph nodes at stations 
10-14 (N1), 1-9 (N2) or both.  Between one and two blocks of formalin-fixed, 
paraffin wax-embedded (FFPE) tissue were studied from the primary tumour 
and between one and five blocks from all involved lymph nodes.  
Accompanying clinical data were available within the LLP database, from case-
note review.  Details of these 107 tumours are given in Table 1.  Ethical 
approval was granted by the Liverpool Research Ethics Committee (reference 
number 97/141).  
2.2 Detection and assessment of PD-L1 expression 
Serial sections 4μm thick were stained with haematoxylin and eosin (H&E) for 
assessment of general morphology and immuno-stained for PD-L1 using the 
Ventana SP263 antibody clone with a validated kit and protocol.19 Slides were 
scanned at x20 magnification to create digital images using the Aperio CS2 
Scanscope slide scanner and Aperio Scancope console software.20 Images were 
viewed using either Aperio ImageScope or the opensource QuPath software 
package.20,21 
Expression of PD-L1 was assessed according to the Roche Ventana SP263 
interpretation guide22 by two pathologists trained and experienced in its 
interpretation and a concordant score agreed in all cases.  The number of PD-
L1+ve tumour cells as a proportion of the total number of tumour cells (the 
tumour proportion score, TPS) was expressed as a percentage.  
2.3 Assessment of heterogeneity 
Intra-tumoural heterogeneity was quantified comparing (a) different samples 
from the same tumour and (b) different samples from its nodal metastases. 
Inter-tumoural heterogeneity was assessed comparing samples from the 
primary tumour with samples from its nodal metastases, and samples from 
separate nodal metastases.  
 
2.3.1 Intra-tumoural heterogeneity 
First, small scale heterogeneity, defined as heterogeneity within an 
approximately 1cm² area of tumour was assessed using a grid split into 1mm 
squares that was overlaid on to the section (Figure 1).  Only sections containing 
a continuous area of viable tumour were assessed; zones of confluent necrosis 
or fibrosis were avoided and sections in which these were extensive were not 
used.  The PD-L1 TPS was assessed for every 1mm square to give 100 readings 
for each area of 1cm².  Between one and three 1cm squares were assessed in 
every section studied by this ‘squares method’ for primary tumours.  Second, 
medium scale heterogeneity, defined as heterogeneity between 1cm squares, 
was examined for primary tumours to give a broader assessment of intra-
tumoural heterogeneity.  Finally, large scale heterogeneity, defined as 
heterogeneity between different tissue blocks, was assessed for primary 
tumours by scoring the entire viable tumour region within each section. Intra-
tumoural heterogeneity of nodal metastases was assessed by scoring any 
overlaid 1mm square with ≥100 tumour cells.  Illustrative examples of intra-
tumoural heterogeneity are shown in Figure 2.  
2.3.2 Inter-tumoural heterogeneity 
With the above data collected for primary and metastatic tumours individually, 
inter-tumoural heterogeneity, that is variability between primary tumours and 
their nodal metastases as well as between different nodal metastases, could 
then be assessed. For both primary and secondary tumours, PD-L1 TPS for 
inter-tumoural comparison was calculated from all available PD-L1 scored 
tissue.  
Finally, an average PD-L1 TPS was calculated for all tumours studied and these 
were then stratified according to the ≥1%, ≥25%, ≥50% cut-offs used to guide 
prescription of IMs.1,3,5-7 
 
 
2.4 Statistical analysis 
Statistical analysis was performed using IBM SPSS statistics software, version 
25 (IBM Corp). Variation of data was described using index of dispersion (IOD) 
and compared using co-efficient of variation (COV). Comparison of COV was 
performed according to Forkman.23 All significances were taken as p<0.05. 
  
3 Results 
3.1 Study population 
Basic demographic, clinical and pathological details of the 107 subjects and 
tumours studied are given in Table 1.  No patient from whom these tumours 
were resected had received neoadjuvant chemotherapy or radiotherapy 
treatment. 
3.2 Intra-tumoural heterogeneity within primary tumours 
3.2.1 Small and Medium Scale Heterogeneity 
There was sufficient quantity and quality (>1cm² of continuous viable tumour 
cells) for assessment by the ‘squares method’ in 50 of the primary tumours and 
in 19 of these there was sufficient tissue for 2 blocks to be studied.  In 16 
tumours, there was sufficient tissue (>2cm² and ≥200 viable tumour cells) for 
assessment of multiple, non-overlapping 1cm² squares in a single section (two 
squares in 14 and three squares in 2) such that 87 1cm² squares were 
ultimately examined. [Dataset] 
Data on small scale heterogeneity, within an area of 1cm², are summarised in 
Table 2.  In 68 primary tumours (78%) the IOD was >1. In the 66 primary 
tumours scoring a TPS of ≥1%, 32 (48%) had a standard deviation (SD) greater 
than their mean. 
Of the 16 specimens assessed for medium scale heterogeneity, 7 specimens 
(44%) had no change in PD-L1 TPS, 9 specimens (56%) had a PD-L1 TPS change 
of ≥1% including 3 specimens (19%) with a PD-L1 TPS change of ≥10%. For 2 
specimens (12.5%), the difference was sufficient to move the PD-L1 TPS across 
the ≥50% clinical guidance cut-off.  
3.2.2 Large scale heterogeneity 
There was sufficient tissue in 61 primary tumours to permit assessment of 
large scale heterogeneity, that is variability between two tissue blocks.  In 33 of 
these (54%), there was no difference in TPS between the two blocks. 28 cases 
(46%) had a TPS change of ≥1% and 17 cases (28%) had a TPS change of ≥10%. 
For 5 cases (8%), the difference was sufficient to move the PD-L1 TPS across a 
clinical guidance cut-off, (1 across ≥25%, 4 across ≥50%).  These data are 
summarised in Table 2.  
 
3.3 Intratumoural heterogeneity within nodal metastases 
In the nodal metastases from 26 cases there was sufficient assessable tumour 
tissue (≥100 viable tumour cells) for assessment of heterogeneity by the 
‘squares method’.  In 19 metastases (73%), the IOD was >1. In the 23 nodal 
metastases scoring a PD-L1 TPS of ≥1%, 6 (23%) had a SD greater than their 
mean.  These results are summarized in Table 2.  
Intra-tumoural heterogeneity within primary tumours as assessed by the 
‘squares method’ had a greater COV than it did in their nodal metastases, but 
the difference was not statistically significant (146 vs 98; p=0.3706). 
3.4 Inter-tumoural heterogeneity  
3.4.1 Primary versus matched nodal metastases 
PD-L1 expression by the primary tumour and its nodal metastases was 
compared in all 107 tumours studied.  In 50 tumours, there was no difference.  
In the remaining 57 (53%) there was a difference of ≥1%, with 30 displaying 
higher expression by the primary than by their nodal metastases and 27 the 
converse.  The median difference in TPS between the primaries and their nodal 
metastases was 10% (range 1-94).  In 25 cases (23%), this difference was 
sufficient to move the TPS across a clinical guidance cut-off.  In 13 cases (12%), 
the PD-L1 TPS was ≥1% in the primary but 0% in its metastases.  In 3 cases 
(3%), the PD-L1 TPS was 0% in the primary, but ≥1% in its metastases.  These 
data are summarised in Table 3 and example shown in Figure 3a and 3b.  
3.4.2 Variation between nodal metastases 
In 35 of the tumours studied, there was sufficient tissue from nodal metastases 
for variation in PD-L1 expression between them to be studied; N1 vs N1 in four 
cases and N1 vs N2 in 31.  In 29 cases (83%), there was no difference between 
stations, including N1 vs N1.  In the remaining 6 cases (17%), the difference 
between N1 and N2 stations was ≥10%.  In all of these, it was sufficient to 
move the TPS across a cut-off.  These results are summarised in Table 3 and 
example shown in Figure 3c and 3d. 
  
4 Discussion 
The extent of expression of PD-L1 as detected by IHC is currently the only 
clinically-validated means of determining the likely response of NSCLC to IMs.1-
4 Characterising and understanding the strengths and limitations of PD-L1 
expression in this context are crucial to improving its predictive power.   
Several studies have attempted to quantify how many biopsy specimens of a 
NSCLC are required to provide accurate coverage of PD-L1 expression within a 
tumour 24-26, many concluding rather obviously that, for example, multiple core 
biopsies are likely to provide greater accuracy than one or two and that 
tumours displaying marked heterogeneity still present significant difficulty.  
The present study concurs with this; increasing quantities of tissue for 
assessment will clearly improve its accuracy, but even a whole tissue section 
might still not be representative of the entire tumour.  Even the detailed and 
extensive study of a large series of tumours that we describe here fails to 
reveal any particular pattern to this heterogeneity, which seems highly variable 
in extent and scale.  This observation holds for not only the primary tumour, 
but also its nodal metastases.  Intra-tumoural heterogeneity is unlikely to be 
random, but reflects ill-understood aspects of the interaction between the 
tumour and the immune environment and underlying clonal variation within 
the tumour. More sophisticated analytical approaches are required to untangle 
these relationships. 
Inter-tumoural heterogeneity of PD-L1 expression is a no less significant 
challenge in terms of achieving high accuracy and predictive power.  Several 
studies have examined PD-L1 expression between a primary NSCLC and its 
metastases 27-29 and, though approaches and methodologies differ, the general 
consensus of these is that expression of PD-L1 varies between tumour sites in 
the majority of cases.  Our investigation supports this, revealing a fairly equal 
divide between tumours in which expression of PD-L1 ‘increases’ or ‘decreases’ 
as they metastasise into regional lymph nodes, with complete loss of PD-L1 
expression during metastasis occurring with more frequency than its apparent 
de novo expression in the environment of the node.  An important observation 
is that this variation between the primary and its metastases was often 
sufficient to cross one of the cut-off thresholds used for guiding management. 
This raises the important question of which score should be acted upon.  It 
would seem reasonable to assume that a tumour deposit expressing high 
levels of PD-L1 would be likely to respond to an IM, whereas a different 
deposit expressing low levels would not; this might be one cause for variable 
response of different lesions of a disseminated tumour.  On the grounds that 
any response would be beneficial, whenever such variability is apparent, it 
would seem appropriate to act on the highest score. 
Ultimately, in the context of NSCLC, expression of PD-L1 is being determined in 
an already heterogeneous population of tumour cells further affected by their 
interaction with the tumour micro-environment (TME) 30.  Immune escape of 
NSCLC is thought to require, in addition to PD-L1 expression, specific 
conditions within the TME, such as the proximity of CD8+ cytotoxic T-cell 
lymphocytes and a non-suppressive immune environment. 31-34 With this in 
mind, it is not surprising that PD-L1 expression varies between a primary 
NSCLC and its nodal metastases; the environment in the lung, especially the 
immune environment, is very different from that in a lymph node. 
Irrespective of its nature, bronchoscopic, transthoracic needle or EBUS-guided, 
there is a high risk that a single diagnostic sample of a NSCLC, primary or 
metastatic, will be inadequately representative for determining something as 
heterogeneous as PD-L1 expression.  Notwithstanding the obvious conclusion 
that greater accuracy is more likely with a larger specimen and, ideally, 
multiple biopsies or aspirates from multiple points within a tumour, it is 
difficult to see how this challenge can be easily overcome.  Not surprisingly, 
therefore, efforts are being made to find an alternative or, more likely, 
complementary biomarkers to use in conjunction with PD-L1 expression and 
improve predictive capabilities, with much current interest focussed on 
tumour mutational burden (TMB) or assessment of the immune environment 
of the tumour. 35-38   
In the interim, however, with PD-L1 expression still the only validated 
biomarker for predicting response of NSCLC to anti-PD-1/PD-L1 IMs, an optimal 
approach to improved tumour sampling may be guided by the intended 
therapeutic target. Neoadjuvant treatment of NSCLC by IMs is being assessed 
in current clinical trials39 and extensive sampling of primary tumour in this 
setting would seem prudent.  Metastasis, however, is a reflection of evolution 
of the tumour, a manifestation of its inherent drive to survival, and it would 
seem reasonable to assume that the most advanced and potentially successful 
component of a disseminated tumour would be the most informative in terms 
of targeting for biopsy. 30,40,41 When metastases are present, therefore, 
sampling and testing of these in preference to the primary growth, whenever 
possible, would seem the most scientifically sound approach and most likely to 
provide informative information. 
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Figure 1 
Title: Intra-tumoural heterogeneity of PD-L1 as assessed by the ‘squares 
method’ 
Description: A section of primary NSCLC immunolabelled for PD-L1 (SP263) 
overlaid with non-overlapping, 1cm² grids (outlined in red), each divided into 
100 1mm squares.  The yellow inset highlights a group of 20 1mm squares.  
Every 1mm square was individually assessed for PD-L1 expression and 
constituted a different data point for examining heterogeneity.   
NSCLC, non-small cell lung cancer; PD-L1, programmed death ligand 1.  
 
Figure 2 (a, b) 
Title: Intra-tumoural heterogeneity of PD-L1 expression; primary tumour   
Description: Two sections of a primary NSCLC immunolabelled for PD-L1 
(SP263).  Figure 2a demonstrates small scale heterogeneity. Figure 2b 
demonstrates large scale heterogeneity. The red arrows highlight tumour cells 
strongly positive for PD-L1, the yellow arrows highlight tumour cells showing 
no expression. 
NSCLC, non-small cell lung cancer; PD-L1, programmed death ligand 1. 
 Figure 3 (a, b, c, d) 
Title: Inter-tumoural heterogeneity of PD-L1 expression 
Description: Sections of a primary NSCLC and nodal metastases 
immunolabelled for PD-L1 (SP263).  Figure 3a demonstrates no expression (0% 
TPS) by the primary tumour, Figure 3b demonstrates diffuse expression (100% 
TPS) in a nodal metastasis from the same patient as indicated by the red oval. 
Figure 3c demonstrates minimal expression (<1% TPS) of PD-L1, as indicated by 
the red oval, in a metastasis in an N1 lymph node, Figure 3d demonstrates 
expression by almost all of the cells (near 100% TPS) as exemplified by the 
zone in the red oval, in a metastasis in a different (N2) lymph node from the 
same patient. 
NSCLC, non-small cell lung cancer; PD-L1, programmed death ligand 1; TPS, 
tumour proportion score 
